The landscape of immunotherapy in metastatic urothelial carcinoma Review


Authors: Teo, M. Y.; Iyer, G.
Review Title: The landscape of immunotherapy in metastatic urothelial carcinoma
Abstract: Purpose of reviewThis review provides an overview of clinical trials recently completed or currently ongoing evaluating the role of checkpoint blockade in metastatic urothelial carcinoma.Recent findingsIn 2016, five immunotherapy agents were approved for metastatic urothelial carcinoma patients who had progressed on platinum-based chemotherapy All five agents evinced an approximately 20% overall response rate coupled with durability of response in a subset of these patients. Several putative predictive biomarkers of sensitivity to checkpoint blockade have been examined although which of these should be incorporated into standard practice is unclear. Moreover, as most patients do not respond to checkpoint blockade, research has focused on combination therapies in both the first-line and second-line settings.SummaryThe durability of response and general tolerability of checkpoint blockade has transformed the treatment of metastatic urothelial carcinoma. However, only a minority of patients responds to single-agent therapy. Potential approaches to overcome this challenge include the incorporation of combination checkpoint blockade as well as chemotherapy and targeted agents. © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Keywords: metastatic urothelial carcinoma; immune checkpoint blockade; predictive biomarkers
Journal Title: Current Opinion in Urology
Volume: 29
Issue: 6
ISSN: 0963-0643
Publisher: Lippincott Williams & Wilkins  
Date Published: 2019-11-01
Start Page: 643
End Page: 648
Language: English
DOI: 10.1097/mou.0000000000000676
PUBMED: 31567441
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gopakumar Vasudeva Iyer
    348 Iyer
  2. Min Yuen   Teo
    105 Teo